Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-gamma enzyme-linked immunospot assay.

Cell-mediated immunity (CMI) is critical for the prevention and control of varicella-zoster virus (VZV)-related disease. To assess CMI to VZV, a varicella skin test and interferon-gamma enzyme-linked immunospot (ELISPOT) assay were both performed in healthy volunteers, and the results were compared. A total of 151 subjects were examined: 16 aged 20-29 years, 26 aged 30-39 years, 18 aged 40-49 years, 73 aged 50-59 years, and 18 aged 60-69 years. All were seropositive by a glycoprotein antigen-based enzyme-linked immunosorbent assay (gpELISA). Skin test reactivity was significantly correlated with the ELISPOT count, and both decreased with increasing age, indicating an age-dependent decline in CMI to VZV. In contrast, the antibody titer obtained by the gpELISA did not correlate with skin test reactivity. The results suggest that the skin test and ELISPOT assay are both reliable for assessing CMI to VZV and can easily be applied to screen individuals susceptible to the development of herpes zoster.

[1]  D. Morton,et al.  Antibody assays suitable for assessing immune responses to live varicella vaccine. , 1991, Vaccine.

[2]  A. Hall,et al.  What does epidemiology tell us about risk factors for herpes zoster? , 2004, The Lancet. Infectious diseases.

[3]  Xu Liu,et al.  Development and Validation of a Gamma Interferon ELISPOT Assay for Quantitation of Cellular Immune Responses to Varicella-Zoster Virus , 2001, Clinical Diagnostic Laboratory Immunology.

[4]  A. Hayward,et al.  Lymphocyte responses to varicella zoster virus in the elderly , 1987, Journal of Clinical Immunology.

[5]  B. LaFleur,et al.  Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. , 1998, The Journal of infectious diseases.

[6]  M. Levin,et al.  Measurement of cell‐mediated immunity with a varicella‐zoster virus‐specific interferon‐γ ELISPOT assay: Responses in an elderly population receiving a booster immunization , 2003, Journal of medical virology.

[7]  J. Hornberger,et al.  Cost-Effectiveness of a Vaccine To Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults , 2006, Annals of Internal Medicine.

[8]  A. Arvin.  Varicella Zoster Virus , 2002 .

[9]  M. Levin,et al.  Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. , 2003, The Journal of infectious diseases.

[10]  E. Trannoy,et al.  A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. , 1998, The Journal of infectious diseases.

[11]  J. Stockman.  A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults , 2007 .

[12]  H. Kamiya,et al.  Diagnostic skin test reactions with varicella virus antigen and clinical application of the test. , 1977, The Journal of infectious diseases.

[13]  H. Yabuuchi,et al.  Studies with live varicella vaccine and inactivated skin test antigen: protective effect of the vaccine and clinical application of the skin test. , 1978, Pediatrics.

[14]  Y. Niho,et al.  High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis. , 1990, Annals of the rheumatic diseases.

[15]  A. Arvin,et al.  Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. , 2002, The New England journal of medicine.

[16]  H. Asada,et al.  Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay. , 2003, Vaccine.

[17]  A. Gershon,et al.  Antibody Responses to Varicella‐Zoster Virus and the Role of Antibody in Host Defense , 1981, The American journal of the medical sciences.

[18]  M. Levin,et al.  Clinical application of responder cell frequency estimates with four years of follow up. , 1994, Journal of immunological methods.

[19]  M. Levin,et al.  Characterization of the human newborn response to herpesvirus antigen. , 1985, Journal of immunology.